NCT06281236View on ClinicalTrials.gov

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

March 25, 2025

Study Completion Date

April 25, 2025

Conditions
Polymyalgia Rheumatica
Interventions
DRUG

Prednisolone

Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.

DRUG

SPI-62

SPI-62 administered once daily.

Trial Locations (5)

19055

Klinische Forschung Schwerin GmbH/Pratia, Schwerin

30159

Klinische Forschung Hannover Mitte GmbH/Pratia, Hanover

55131

Universitätsmedizin der Johannes Gutenburg Universität Mainz, Mainz

80336

Klinikum der Universität München, München

Unknown

Emovis Gmbh, Berlin

Sponsors
All Listed Sponsors
lead

Sparrow Pharmaceuticals

INDUSTRY

NCT06281236 - A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) | Biotech Hunter | Biotech Hunter